SUPN Share Price

Open 22.50 Change Price %
High 23.20 1 Day 0.70 3.14
Low 22.45 1 Week 1.20 5.50
Close 23.00 1 Month 2.50 12.20
Volume 648479 1 Year 8.76 61.52
52 Week High 26.84
52 Week Low 9.51
SUPN Important Levels
Resistance 2 23.70
Resistance 1 23.41
Pivot 22.88
Support 1 22.59
Support 2 22.30
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

SUPN Technical Analysis 3
As on 9th Dec 2016 SUPN Share Price closed @ 23.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 18.76 & Buy for SHORT-TERM with Stoploss of 22.12 we also expect STOCK to react on Following IMPORTANT LEVELS.
SUPN Target for December
1st Target up-side 25.64
2nd Target up-side 28.5
3rd Target up-side 31.37
1st Target down-side 17.46
2nd Target down-side 14.6
3rd Target down-side 11.73
SUPN Other Details
Segment EQ
Market Capital 306384160.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.supernus.com
SUPN Address
SUPN
1550 East Gude Drive
Rockville, MD 20850
United States
Phone: 301-838-2500
Interactive Technical Analysis Chart Supernus Pharmaceuticals, Inc. ( SUPN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Supernus Pharmaceuticals, Inc.
SUPN Business Profile
Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.